CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia
Authors
William T. Abraham
Daniel G. Bichet
+8 more
Guy Decaux
for the HARMONY Study Group
Richard C. Josiassen
Nelson Kopyt
Massimo Mannelli
Cesare Orlandi
Hemant P. Thacker
Yoram Yagil
Publication date
1 December 2012
Publisher
Doi
Cite
Abstract
Hyponatremia is the most common electrolyte disorder in clinical practice. Its incidence increases with age and it is associated with increased morbidity and mortality. Recently, the vaptans, antagonists of the arginine vasopressin pathway, have shown promise for safe treatment of hyponatremia. Here we evaluated the efficacy, safety, and tolerability of oral lixivaptan, a selective vasopressin V2-receptor antagonist, for treatment of nonhospitalized individuals with euvolemic hyponatremia (sodium less than 135 mmol/l) in a multicenter, randomized, double-blind, placebo-controlled, phase III study. About half of the 206 patients were elderly in a chronic care setting. Of these patients, 52 were given a placebo and 154 were given 25-100 mg per day lixivaptan, titrated based on the daily serum sodium measurements. Compared with placebo (0.8 mmol/l), the serum sodium concentration significantly increased by 3.2 mmol/l from baseline to day 7 (primary efficacy endpoint) with lixivaptan treatment. A significantly greater proportion of patients that received lixivaptan achieved normal serum sodium (39.4%) by day 7 relative to placebo (12.2%). Overall, lixivaptan was considered safe and well-tolerated. Thus, oral lixivaptan can be safely initiated in the outpatient setting and effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. © 2012 International Society of Nephrology.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Elsevier - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 05/06/2019
DI-fusion
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:dipot.ulb.ac.be:2013/18305...
Last time updated on 23/02/2017
Lehigh Valley Health Network: LVHN Scholarly Works
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:scholarlyworks.lvhn.org:me...
Last time updated on 14/07/2022
Elsevier - Publisher Connector
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 06/05/2017